

COMPANY OVERVIEW

VistaGen Therapeutics (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's CNS drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, a favorable safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets.

RECENT NEWS

VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Feb 10 2022, 4:20 PM EST

STOCK OVERVIEW

Symbol	VTGN
Exchange	Nasdaq
Market Cap	282.94m
Last Price	\$1.37
52-Week Range	\$1.26 - \$3.55

03/02/2022 04:00 PM EST

INVESTOR RELATIONS

VistaGen Therapeutics
Mark Flather
Vice President, Investor Relations
+1(650) 577-3617
mflather@vistagen.com

MANAGEMENT TEAM

Shawn K. Singh, J.D.

Chief Executive Officer and Director

H. Ralph Snodgrass, Ph.D.

President and Chief Scientific Officer

Ann Cunningham, MBA

Chief Commercial Officer and Director

Jerrold D. Dotson, CPA

Vice President, Chief Financial Officer and Secretary

Mark A. Smith, M.D., Ph.D.

Chief Medical Officer

Allen (Jo) Cato, III, Ph.D.

Senior Vice President, Development Operations

Mark J. Ginski, Ph.D.

Senior Vice President, Head of CMC

Jaakko Lappalainen, M.D., Ph.D.

Senior Vice President, Global Clinical Development & Pharmacovigilance

Ross A. Baker, Ph.D., MBA

Vice President, Global Medical Affairs

Erik Berglund, M.D., Ph.D., R.A.C.

Vice President, Global Regulatory Affairs

Mark Flather

Vice President, Investor Relations

Rita E. Hanover, Ph.D., R.A.C.

Vice President, Biostatistics and Clinical Analytics

Mark A. McPartland

Vice President of Corporate Development

Louis Monti, M.D., Ph.D.

Vice President, Translational Medicine

Joshua Prince, MBA

Vice President, Strategic Insights & Analytics

Ellis Wilson, Jr., M.S., E.M.B.A.

Vice President, Global Clinical Operations

VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue
South San Francisco, CA 94080

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.